Bumper debut! Hamps Bio lists at 90% premium, hits upper circuit later

After listing, the Hamps Bio shares gained an additional 5 per cent, surging 99.49 per cent from the issue price to reach the upper circuit of Rs 101.74 apiece on the BSE SME

Equity markets around the world continue to be on a tear. The MSCI Global Equity Index is close to its lifetime highs, up a staggering 30 per cent over the last year. But it is not just equities; all asset classes have thrived in recent months.
Kumar Gaurav New Delhi
2 min read Last Updated : Dec 20 2024 | 11:06 AM IST
Hamps Bio IPO listing today: Shares of Hamps Bio made a solid debut on the BSE SME today, Friday, December 20, 2024, continuing their upward momentum to hit the upper circuit within a few minutes of listing. The company's stock listed at Rs 96.90 apiece, a 90 per cent premium over the IPO allotment price of Rs 51.
 
After listing, the Hamps Bio shares gained an additional 5 per cent, surging 99.49 per cent from the issue price to reach the upper circuit of Rs 101.74 apiece on the BSE SME. During the session, nearly 0.28 million shares, valued at Rs 2.90 crore, were traded before trading was halted.  ALSO READ: Ventive Hospitality IPO opens; check GMP, recommendation and other details
 
Hamps Bio IPO listing aligns with grey market trends, as the company’s shares were commanding a solid premium in unofficial markets. Ahead of the listing, Hamps Bio shares were trading at Rs 111 apiece, reflecting a grey market premium (GMP) of Rs 60 or 117.65 per cent over the issue price, revealed sources tracking grey market activities.
 
The SME offering of Hamps Bio, comprising a fresh issue of 12,20,000 equity shares at Rs 51 apiece, received enthusiastic participation from investors. The public offering, which was available for subscription from Friday, December 13, 2024, till Tuesday, December 17, 2024, ended with getting oversubscribed by a whopping 1,003.33 times, according to BSE data.
 
Hamps Bio will utilise the proceeds from the public offering for the purchase of plant & machinery for the FMCG division and for enhancing the visibility and awareness of the brand. The company will also use the proceeds for general corporate purposes.
 
Hamps Bio is a pharmaceutical company engaged in the marketing and distribution of pharmaceutical formulation products. The company's product portfolio includes a wide range of dosage forms, such as tablets, syrups, capsules, injectables, oils, gels, and powders, which are used as medicines and nutritional supplements. In addition to its pharmaceutical business, the company also manufactures and supplies freeze-dried and frozen products, including fruits, vegetables, herbs, and flowers.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :IPO listing timeSME IPOShare priceBuzzing stocksIPO GMP

First Published: Dec 20 2024 | 10:14 AM IST

Next Story